Goldman Sachs
FLNA

Goldman Sachs’s Filana Therapeutics FLNA Stock Holding History

Goldman Sachs’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,800
Closed -$220K – 6036
2024
Q2 		$220K Buy
+17,800
New +$375K ﹤0.01% 5222
2016
Q4 		– Sell
-357
Closed -$2K – 7064
2016
Q3 		$2K Buy
+357
New +$5.92K ﹤0.01% 6969
2013
Q3 		– Sell
-4,643
Closed -$72K – 6673
2013
Q2 		$72K Buy
+4,643
New +$98.1K ﹤0.01% 5963

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's FLNA Position: Q2 2026 in Review

Goldman Sachs increased its Filana Therapeutics (FLNA) stake by 1,518% in Q2 2026, buying an estimated $894K and bringing the position to 668,792 shares worth $796K. The position accounts for ﹤0.01% of the portfolio, ranked #5396.

Goldman Sachs first reported a position in FLNA in Q2 2013 and has held it in 35 quarters since. The position peaked at $5.57M in Q2 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Goldman Sachs held 668,792 shares of Filana Therapeutics worth $796K as of Q2 2026.
  • Goldman Sachs bought 627,468 Filana Therapeutics shares in Q2 2026, an estimated $894K.
  • Filana Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5396 holding.
  • Goldman Sachs first reported a position in Filana Therapeutics in Q2 2013 and has held it in 35 quarters since.
  • Goldman Sachs's Filana Therapeutics position peaked at $5.57M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.